NYSE:HIMS Hims & Hers Health (HIMS) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free HIMS Stock Alerts $12.50 +0.23 (+1.87%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$12.31▼$12.7450-Day Range$9.40▼$16.7252-Week Range$5.65▼$17.16Volume3.60 million shsAverage Volume4.24 million shsMarket Capitalization$2.68 billionP/E RatioN/ADividend YieldN/APrice Target$14.85 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Hims & Hers Health alerts: Email Address Hims & Hers Health MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.62 Rating ScoreUpside/Downside18.8% Upside$14.85 Price TargetShort InterestBearish12.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 4 Articles This WeekInsider TradingSelling Shares$7.33 M Sold Last QuarterProj. Earnings Growth130.00%From $0.10 to $0.23 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.45 out of 5 starsMedical Sector314th out of 913 stocksOffices & Clinics Of Medical Doctors Industry1st out of 7 stocks 3.3 Analyst's Opinion Consensus RatingHims & Hers Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 8 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageHims & Hers Health has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.52% of the float of Hims & Hers Health has been sold short.Short Interest Ratio / Days to CoverHims & Hers Health has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hims & Hers Health has recently increased by 34.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHims & Hers Health does not currently pay a dividend.Dividend GrowthHims & Hers Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HIMS. Previous Next 2.5 News and Social Media Coverage News SentimentHims & Hers Health has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Hims & Hers Health this week, compared to 6 articles on an average week.Search InterestOnly 34 people have searched for HIMS on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.MarketBeat Follows31 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 41% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,327,717.00 in company stock.Percentage Held by Insiders31.63% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Hims & Hers Health are expected to grow by 130.00% in the coming year, from $0.10 to $0.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hims & Hers Health is -113.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hims & Hers Health is -113.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHims & Hers Health has a P/B Ratio of 7.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Hims & Hers Health Stock (NYSE:HIMS)Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.Read More HIMS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HIMS Stock News HeadlinesApril 19, 2024 | insidertrades.comSoleil Boughton Sells 2,503 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) StockApril 9, 2024 | insidertrades.comMelissa Baird Sells 11,751 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) StockApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 9, 2024 | insidertrades.comHims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 188,888 SharesApril 3, 2024 | insidertrades.comInsider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 2,503 Shares of StockApril 22, 2024 | businesswire.comExowatt Launches with $20 Million to Modernize Data Center Power for the AI EraApril 20, 2024 | nasdaq.comRelative Strength Alert For Hims & Hers HealthApril 19, 2024 | fool.comWhy Hims & Hers Stock Was Down This WeekApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 18, 2024 | msn.comWhat to Know About 'Sexual Enhancement' Pills and Boosting Testosterone LevelsApril 18, 2024 | investing.comHims & Hers Health's chief legal officer sells over $34k in company stockApril 18, 2024 | americanbankingnews.comHims & Hers Health (NYSE:HIMS) Shares Gap Down to $13.22April 17, 2024 | investorplace.comThe Disruptor's Portfolio: 3 Stocks Shaping the New EconomyApril 17, 2024 | msn.comJefferies Downgrades Hims & Hers Health (HIMS)April 17, 2024 | americanbankingnews.comHims & Hers Health (NYSE:HIMS) Given Hold Rating at Jefferies Financial GroupApril 16, 2024 | finance.yahoo.comJefferies downgrades Hims & Hers Health on growth concernsApril 16, 2024 | benzinga.comUnpacking the Latest Options Trading Trends in Hims & Hers HealthApril 16, 2024 | msn.comHims & Hers slips as Jefferies cuts on valuationApril 15, 2024 | businesswire.comHims & Hers to Announce First Quarter 2024 Financial Results on May 6, 2024April 11, 2024 | markets.businessinsider.comHims & Hers Health Outperforms: Strong Sales Growth and Brand Value Reinforce Buy RatingApril 10, 2024 | investing.comHims & Hers Health CEO sells over $4.9 million in company stockApril 10, 2024 | benzinga.comBreaking Down Hims & Hers Health: 6 Analysts Share Their ViewsApril 8, 2024 | finance.yahoo.comHims & Hers Health, Inc. (NYSE:HIMS) Is About To Turn The CornerApril 6, 2024 | msn.comGot $2,000? 2 Unbelievable Growth Stocks Up 58% and 30% to Buy in the New Bull MarketApril 5, 2024 | seekingalpha.comHims & Hers Health: Strong Prospects But Weak Business Model ConsolidationApril 5, 2024 | msn.comChisago County Sheriff's Office uses drone to help person experiencing mental health crisisApril 4, 2024 | benzinga.comA Closer Look at Hims & Hers Health's Options Market DynamicsSee More Headlines Receive HIMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today4/27/2024Next Earnings (Confirmed)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Offices & clinics of medical doctors Sub-IndustryN/A Current SymbolNYSE:HIMS CUSIPN/A CIK1773751 Webwww.forhims.com Phone415-851-0195FaxN/AEmployees1,046Year FoundedN/APrice Target and Rating Average Stock Price Target$14.85 High Stock Price Target$20.00 Low Stock Price Target$10.00 Potential Upside/Downside+18.8%Consensus RatingModerate Buy Rating Score (0-4)2.62 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($0.11) Trailing P/E RatioN/A Forward P/E Ratio125.00 P/E GrowthN/ANet Income$-23,550,000.00 Net Margins-2.70% Pretax Margin-2.47% Return on Equity-7.21% Return on Assets-5.81% Debt Debt-to-Equity RatioN/A Current Ratio3.00 Quick Ratio2.74 Sales & Book Value Annual Sales$872 million Price / Sales3.07 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book7.76Miscellaneous Outstanding Shares214,250,000Free Float146,483,000Market Cap$2.68 billion OptionableOptionable Beta0.91 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Andrew Dudum (Age 35)Co-Founder, Chairman & CEO Comp: $1.7MMr. Yemi Okupe (Age 38)Chief Financial Officer Comp: $804.05kMs. Melissa Baird (Age 46)Chief Operating Officer Comp: $917.67kMs. Irene A. Becklund (Age 39)Senior VP, Controller & Principal Accounting Officer Comp: $361.12kMs. Soleil Teubner Boughton (Age 45)Chief Legal Officer & Corporate Secretary Comp: $782.66kMr. Mike Chi (Age 43)Chief Marketing Officer Comp: $514.77kDr. Patrick Carroll M.D. (Age 66)Chief Medical Officer, Member of Medical Advisory Board & Director Comp: $27.03kMs. Khobi BrooklynChief Communications OfficerMs. Amee ParekhSenior Vice President of Human ResourcesDr. Peter Stahl M.D.Senior VP & Member of Medical Advisory BoardMore ExecutivesKey CompetitorsTeladoc HealthNYSE:TDOCSummit TherapeuticsNASDAQ:SMMTNeogenNASDAQ:NEOGQuidelOrthoNASDAQ:QDELCertaraNASDAQ:CERTView All CompetitorsInsiders & InstitutionsFirst National Trust CoBought 15,000 shares on 4/26/2024Ownership: 0.007%Simplex Trading LLCBought 67,800 shares on 4/25/2024Ownership: 0.000%Summit Trail Advisors LLCBought 176,612 shares on 4/23/2024Ownership: 0.126%Lake Street Private Wealth LLCBought 42,037 shares on 4/19/2024Ownership: 0.020%Cullinan Associates Inc.Sold 24,842 shares on 4/18/2024Ownership: 0.035%View All Insider TransactionsView All Institutional Transactions HIMS Stock Analysis - Frequently Asked Questions Should I buy or sell Hims & Hers Health stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HIMS shares. View HIMS analyst ratings or view top-rated stocks. What is Hims & Hers Health's stock price target for 2024? 13 Wall Street research analysts have issued 1 year target prices for Hims & Hers Health's shares. Their HIMS share price targets range from $10.00 to $20.00. On average, they expect the company's stock price to reach $14.85 in the next twelve months. This suggests a possible upside of 18.8% from the stock's current price. View analysts price targets for HIMS or view top-rated stocks among Wall Street analysts. How have HIMS shares performed in 2024? Hims & Hers Health's stock was trading at $8.90 at the start of the year. Since then, HIMS shares have increased by 40.4% and is now trading at $12.50. View the best growth stocks for 2024 here. Are investors shorting Hims & Hers Health? Hims & Hers Health saw a increase in short interest in April. As of April 15th, there was short interest totaling 17,470,000 shares, an increase of 34.6% from the March 31st total of 12,980,000 shares. Based on an average daily volume of 5,020,000 shares, the days-to-cover ratio is currently 3.5 days. Currently, 12.5% of the company's shares are short sold. View Hims & Hers Health's Short Interest. When is Hims & Hers Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our HIMS earnings forecast. How can I listen to Hims & Hers Health's earnings call? Hims & Hers Health will be holding an earnings conference call on Monday, May 6th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were Hims & Hers Health's earnings last quarter? Hims & Hers Health, Inc. (NYSE:HIMS) posted its quarterly earnings data on Monday, February, 26th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.03. The business earned $246.60 million during the quarter, compared to analysts' expectations of $245.84 million. Hims & Hers Health had a negative net margin of 2.70% and a negative trailing twelve-month return on equity of 7.21%. Hims & Hers Health's revenue was up 47.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.05) EPS. What ETFs hold Hims & Hers Health's stock? ETFs with the largest weight of Hims & Hers Health (NYSE:HIMS) stock in their portfolio include Amplify Online Retail ETF (IBUY), Global X Telemedicine & Digital Health ETF (EDOC), SPDR S&P Health Care Services ETF (XHS), Fidelity Digital Health ETF (FDHT), iShares Virtual Work and Life Multisector ETF (IWFH), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Healthcare Providers ETF (IHF). What guidance has Hims & Hers Health issued on next quarter's earnings? Hims & Hers Health updated its first quarter 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $267.0 million-$272.0 million, compared to the consensus revenue estimate of $251.3 million. Who are Hims & Hers Health's major shareholders? Hims & Hers Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Summit Trail Advisors LLC (0.13%), State of Michigan Retirement System (0.08%), Simplex Trading LLC (0.00%), Cullinan Associates Inc. (0.03%), Lake Street Private Wealth LLC (0.02%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Alex Bard, Andrew Dudum, David B Wells, David B Wells, Irene Becklund, Jack Abraham, Jules A Maltz, Lynne Chou O'keefe, Melissa Baird, Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee. View institutional ownership trends. How do I buy shares of Hims & Hers Health? Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:HIMS) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hims & Hers Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
